Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations.

David C Johnson, BSc, Walter M Gregory, PhD, Nicholas J Dickens, DPhil, Brian A Walker, PhD, Alex J Szubert, MSc, Faith E Davies, MD, Brian G M Durie, MD, Brian G Van Ness, PhD, Gareth J Morgan, MD, PhD

Blood (2009) 114 (22): 426.

https://doi.org/10.1182/blood.V114.22.426.426

Published: 2009

Journal Articles

Integration of Gene Mapping and Expression Arrays Identifies Mechanisms by Which Genes Are Dysregulated as a Result of Copy Number Loss and Gain Associated with IgH Translocations in Multiple Myeloma.

Matthew W. Jenner, MD, Gonzalez David, PhD, Paola E. Leone, PhD, Brian A. Walker, PhD, David C. Johnson, BSc, Nicholas J. Dickens, PhD, Fiona M. Ross, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD, PhD

Blood (2007) 110 (11): 395.

https://doi.org/10.1182/blood.V110.11.395.395

Published: 2007

Journal Articles

An Integrated Pharmacogenomic Strategy for the Definition of Thalidomide Response Signatures in Presenting Cases of Multiple Myeloma.

Gareth J. Morgan, MD, PhD, Matthew W. Jenner, MD, Brian A. Walker, PhD, David C. Johnson, BSc, Paola A. Leone, PhD, Fiona M. Ross, PhD, Mark T. Drayson, MD, PhD, Brian G. Van Ness, Brian G. Durie, Nicholas J. Dickens, PhD, J. Anthony Child, R.G. Owen, Faith E. Davies, MD

Blood (2007) 110 (11): 2493.

https://doi.org/10.1182/blood.V110.11.2493.2493

Published: 2007

Journal Articles

Mutation and Methylation Analysis of WWOX and CYLD on 16q; Potential Tumor Suppressor Genes in Myeloma.

Brian A. Walker, PhD, Matthew W. Jenner, MD, Poala E. Leone, PhD, Nicholas J. Dickens, DPhil, David C. Johnson, BSc, Fiona M. Ross, DPhil, Faith E. Davies, MD, Gareth J. Morgan, MD, PhD

Blood (2007) 110 (11): 2473.

https://doi.org/10.1182/blood.V110.11.2473.2473

Published: 2007

Journal Articles

Screening of Homozygous Deletions Identifies Key Deregulated Genes and Pathways in Multiple Myeloma.

Paola E. Leone, PhD, Brian A. Walker, PhD, Nicholas J. Dickens, DPhil, Matthew W. Jenner, MD, David C. Johnson, BSc, Fiona M. Ross, DPhil, Faith E. Davies, MD, Gareth J. Morgan, MD, PhD

Blood (2007) 110 (11): 2474.

https://doi.org/10.1182/blood.V110.11.2474.2474

Published: 2007

Journal Articles

The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.

Gareth J. Morgan, MD, PhD, David C. Johnson, BSc, John Crowley, PhD, John Shaughnessy, Jr., PhD, Pieter Sonneveld, MD, Brian Durie, MD, Christine Ramos, PhD, Brian G. Van Ness, PhD, Bart Barlogie, MD, Antje Hoering, PhD, Jeff Haessler, PhD, Dalsu Baris, MD, PhD, Michael Katz, BS, Vincent S. Rajkumar, MD, H. Goldschmidt, MD

Blood (2006) 108 (11): 246.

https://doi.org/10.1182/blood.V108.11.246.246

Published: 2006

Journal Articles

Sub-Classification of Hyperdiploid Myeloma Using Global Gene Expression Profiling and SNP-Based Mapping Arrays.

Brian A. Walker, PhD, Paola E. Leone, PhD, Matthew W. Jenner, MD, David C. Johnson, BSc, David Gonzalez, PhD, Mark T. Drayson, PhD, Fiona M. Ross, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD PhD

Blood (2006) 108 (11): 3390.

https://doi.org/10.1182/blood.V108.11.3390.3390

Published: 2006

Journal Articles

Abnormalities of 16q in Multiple Myeloma Are Associated with Poor Prognosis: 500K Gene Mapping and Expression Correlations Identify Two Potential Tumor Suppressor Genes, WWOX and CYLD .

Matthew W. Jenner, MD, Paola E. Leone, PhD, Brian A. Walker, PhD, David C. Johnson, BSc, Laura Chiecchio, MSc, Elisabet Dachs Cabanas, BSc, Gian Paolo Dagrada, MSc, Mathew Nightingale, Rebecca K.M. Protheroe, BSc, David Stockley, BSc, Monica Else, MSc, Fiona M. Ross, PhD, Nicholas C.P. Cross, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD, PhD

Blood (2006) 108 (11): 110.

https://doi.org/10.1182/blood.V108.11.110.110

Published: 2006

Journal Articles

Fine Mapping and Expression Analysis of Chromosome 1 with the Aim of Defining Critically Deregulated Genes Important in the Pathogenesis of Myeloma.

Paola E. Leone, PhD, Matthew W. Jenner, MD, Brian A. Walker, PhD, David C. Johnson, BSc, David Gonzalez, PhD, Fiona M. Ross, PhD, Faith E. Davies, MD, Gareth J. Morgan, MD, PhD

Blood (2006) 108 (11): 112.

https://doi.org/10.1182/blood.V108.11.112.112

Published: 2006

Journal Articles

Inherited Genetic Variation and the Risk of Developing Venous Thrombosis with Thalidomide Treatment in Myeloma Patients.

David C. Johnson, BSc, Suzanne Grindle, BS, Faith Davies, MD, David Gonzalez, PhD, Christine Ramos, PhD, Kim Hawkins, MSc, Suzanne Bell, PhD, Heather Kesby, BSc, S. Vincent Rajkumar, MD, Erik Rassmusen, PhD, John Crowley, PhD, Emily Blood, PhD, J. Anthony Child, MD, Brian G.M. Durie, MD, Brian G. Van Ness, PhD, Gareth J. Morgan, MDPhD

Blood (2005) 106 (11): 1624.

https://doi.org/10.1182/blood.V106.11.1624.1624

Published: 2005

Journal Articles

Development of a Panel of 3,500 SNP Based Functional Genetic Variants Relevant to the Etiology and Outcome in Multiple Myeloma.

David C. Johnson, BSc, Suzanne M. Grindle, BS, Christine Ramos, PhD, Faith Davies, MD, David Gonzalez, PhD, Brian A. Walker, PhD, Brian G.M. Durie, MD, Brian G. Van Ness, Phd, Gareth J. Morgan, MD, PhD

Blood (2005) 106 (11): 620.

https://doi.org/10.1182/blood.V106.11.620.620

Published: 2005

NARROW

Genetic Variations Associated with Overall and Progression-Free Survival in Multiple Myeloma Patients Treated with Thalidomide Combinations.

Integration of Gene Mapping and Expression Arrays Identifies Mechanisms by Which Genes Are Dysregulated as a Result of Copy Number Loss and Gain Associated with IgH Translocations in Multiple Myeloma.

An Integrated Pharmacogenomic Strategy for the Definition of Thalidomide Response Signatures in Presenting Cases of Multiple Myeloma.

Mutation and Methylation Analysis of WWOX and CYLD on 16q; Potential Tumor Suppressor Genes in Myeloma.

Screening of Homozygous Deletions Identifies Key Deregulated Genes and Pathways in Multiple Myeloma.

The Genetic Contribution to the Aetiology of Thalidomide Associated VTE.

Sub-Classification of Hyperdiploid Myeloma Using Global Gene Expression Profiling and SNP-Based Mapping Arrays.

Abnormalities of 16q in Multiple Myeloma Are Associated with Poor Prognosis: 500K Gene Mapping and Expression Correlations Identify Two Potential Tumor Suppressor Genes, WWOX and CYLD .

Fine Mapping and Expression Analysis of Chromosome 1 with the Aim of Defining Critically Deregulated Genes Important in the Pathogenesis of Myeloma.

Inherited Genetic Variation and the Risk of Developing Venous Thrombosis with Thalidomide Treatment in Myeloma Patients.

Development of a Panel of 3,500 SNP Based Functional Genetic Variants Relevant to the Etiology and Outcome in Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only